BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer

 
• By Joseph Haas
  
Lung Cancer
BMS is looking to move into earlier lines of NSCLC therapy with Opdivo
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer